Publication Name	World Journal of Gastroenterology
Manuscript ID	16923
Country	Germany

Received	2015-02-03 08:47
Peer-Review Started	2015-02-05 19:06
To Make the First Decision	2015-04-24 19:18
Return for Revision	2015-04-26 16:02
Revised	2015-05-12 01:25
Second Decision	2015-07-17 16:59
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2015-07-18 11:09
Articles in Press	2015-07-18 11:09
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-08-05 15:53
Publish the Manuscript Online	2015-08-20 13:37

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Perspectives in the treatment of pancreatic adenocarcinoma
Manuscript Source	Invited Manuscript
All Author List	Angel Cid-Arregui and Victoria Juarez
Funding Agency and Grant Number
Corresponding Author	Angel Cid-Arregui, MD, PhD, German Cancer Research Center, Translational Immunology, Tumor Immunology Program, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. a.cid@dkfz.de
Key Words	Pancreatic adenocarcinoma; Tumor surveillance; Biomarkers; Immune surveillance; Chemotherapy; Immunotherapy; Antibody therapy; Adoptive T cell therapy; Vaccines; Stroma; Inhibitors
Core Tip	Pancreatic adenocarcinoma is a life threatening, fast evolving disease for which there is no cure. Recently, new chemotherapy regimens have shown significant improvement in survival in patients with advanced disease, opening a way for further progress. New therapeutic strategies based on targeted inhibitors or immunotherapy approaches, in particular antibody and adoptive T cell therapies, are getting growing attention as they are proving beneficial in pre-clinical and early phase clinical studies in combination with chemotherapy. Progress in understanding pancreatic tumor genetics, epigenetics and metabolism is providing new biomarkers that may be of value in early detection and progression assessments.
Publish Date	2015-08-20 13:37
Citation	Cid-Arregui A, Juarez V. Perspectives in the treatment of pancreatic adenocarcinoma. World J Gastroenterol 2015; 21(31): 9297-9316
URL	http://www.wjgnet.com/1007-9327/full/v21/i31/9297.htm
DOI	http://dx.doi.org/10.3748/wjg.v21.i31.9297

Full Article (PDF)	WJG-21-9297.pdf
Full Article (Word)	WJG-21-9297.doc
Manuscript File	16923-Review.docx
Answering Reviewers	16923-Answering reviewers.pdf
Audio Core Tip	16923-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	16923-Conflict-of-interest statement.pdf
Copyright License Agreement	16923-Copyright assignment.pdf
Peer-review Report	16923-Peer-review(s).pdf
Scientific Misconduct Check	16923-Scientific misconduct check.pdf
Scientific Editor Work List	16923-Scientific editor work list.pdf